Aleafia Health (TSX:ALEF,OTCQX:ALEAF) is expanding its presence in the Australian cannabis market as the company confirmed the distribution of its brand new white label medical oils in the country.
On Thursday (November 28), the Canadian licensed producer (LP) told investors it completed the initial run of its premium medical cannabis oil brand, Circle, which will be distributed by Montu Group, its Victoria-based partner.
Aleafia Health said the shipment is expected to be sent out later this year once it receives the necessary permits from Health Canada, the federal regulator of cannabis products.
While the shipment represents the start of Aleafia Health’s international white label production services, CEO Geoffrey Benic said this development will also help establish the position of the company in Australia’s budding cannabis industry.
“With the strength of our existing local distribution network and investments, we are increasing our Australian footprint, as we also deploy our cannabis education platform and clinic operations expertise,” the executive said in a statement.
Montu Group is now offering medical cannabis patients in Australia with Circle’s line of cannabidiol (CBD) and tetrahydrocannabinol (THC) oils.
Christopher Strauch, Montu Group’s managing director, said thanks to the quickly growing network of doctors giving access to quality cannabis products, Australia will serve as a key piece in Montu Group’s international expansion strategy.
Aleafia Health continues movement towards Australian presence
This marks one of a series of moves by the company to push into the Australian market.
In November 2018, the company announced it was starting its global expansion in the country with the proposal of a 10 percent equity stake in CannaPacific, a licensed Australian medical cannabis company based in New South Wales.
Aleafia Health also noted that due to Australia’s proximity to Asia, the partnership could be a plus for the company in terms of giving access to potential future free trade deals.
The deal was solidified in January when Aleafia Health paid CannaPacific AU$100 per share for its 10 percent stake and contributed US$150,000, and it furthered in April when the LP more than doubled its investment after it purchased AU$540,000 worth of ordinary shares in the Australian firm.
Its relationship with CannaPacific paid off earlier this year in July when Aleafia Health got its hands on export permits from Health Canada, allowing Aleafia Health to fully leverage its relationship with the Australian producer.
The permits were a first for Aleafia Health’s plans for global distribution.
As part of its Q3 2019 results, the Canadian producer reported that its partnership with CannaPacific has paid off since its medical cannabis oils became available to patients in Australia.
Shares of Aleafia Health sit at C$0.63 on Tuesday (December 3) as of 11:31 a.m. EST.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.